Argenx

This study tested two different dosing schedules for an intravenous drug called efgartigimod in adults with generalized myasthenia gravis (gMG), a condition that causes muscle weakness. Researchers wanted to see if giving the drug continuously worked better than giving it in cycl…

This study followed 24 adults with primary Sjögren's syndrome to check the long-term safety of a drug called efgartigimod. All participants had already finished a previous study with the same drug and continued treatment without interruption. The main goal was to monitor for side…

This study tested the long-term safety and effectiveness of a drug called efgartigimod for adults with primary immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, increasing bleeding risk. Over 100 patients received intravenous infusions for up t…

This study tested the long-term safety and effectiveness of a medication called efgartigimod, given as an injection under the skin, for people with generalized myasthenia gravis (gMG). It involved 184 adults who had previously benefited from the treatment in earlier studies. The …

This study tested whether adding an intravenous drug called efgartigimod to standard treatment could better control lupus nephritis, a serious kidney complication of lupus. It involved 73 Chinese adults with active kidney inflammation from lupus. The main goal was to see if the d…

This study tested whether efgartigimod injections could help adults with moderate to severe bullous pemphigoid, a rare autoimmune disease that causes painful skin blisters. Researchers compared the injection against a placebo in 98 participants to see if it could control disease …

This was an early-stage study to check the safety of a new drug called ARGX-109 in healthy adults. Researchers gave a single injection to 40 volunteers and monitored them for about 20 weeks to see how their bodies reacted to the drug and how it moved through their system. The mai…